Biotron Limited
Research Biotron Limited (BIT.AX) on Bullrun: market cap AUD 5.57M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBIT.AX
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 5.57M
- Financial periodFY2024
- Net income-AUD 3.44M
- Free cash flow-AUD 3.57M
Valuation Snapshot
latest market cap is AUD 5.57M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | n/a | -AUD 3.44M | -AUD 3.57M | n/a | 0 | AUD 393.20K | AUD 7.13K | -AUD 244.03K |
| FY2023 | n/a | -AUD 3.49M | -AUD 3.29M | n/a | 0 | AUD 3.98M | AUD 45.27K | AUD 3.17M |
| FY2022 | n/a | -AUD 2.78M | -AUD 2.44M | n/a | 0 | AUD 1.74M | AUD 77.24K | AUD 1.09M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-16 | AUD 5.57M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 AUD.
About Biotron Limited
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Biotron Limited's market cap?
Biotron Limited's market capitalization is AUD 5.57M.
What does Biotron Limited do?
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225 that is in Phase 2 clinical trial for the treatment of HIV-1, as well as to treat hepatitis C virus infections; and BIT-HBV001 to treat hepatitis B virus and hepatitis delta virus. It also develops preclinical drugs for viral diseases, such as dengue, zika, and influenza virus. The company was incorporated in 1999 and is based in Sydney, Australia.